Clinical Trials

Volunteers are needed for a study on the microbiome of subjects with and without vitiligo. For patients with vitiligo and without vitiligo, the study will include an initial visit, at which time swab or tape strip samples of the skin and swab samples of stool will be collected. All subjects will be asked to complete questionnaires about their skin care regimen and dietary habits. Subjects with vitiligo will be required to follow up for additional specimen collection and questionnaire completion after six months and one year.

The purpose of this study is to understand the possible burden of skin disorders in school-age children, such as its impact on the development of anxiety, depression and relationships with friends. The study will look at the relationship between the burden and how severe or visible the skin problem is.​ Surveys can be done remotely.

The purpose of this study is to test flexible body-worn sensors and video technology to provide high-resolution measures of motor development in infants, starting from a very young age and continuing up to 2 years of age.

This study will enroll up to 200 infants: 100 infants expected to have typical motor development and 100 infants at risk of atypical motor development (based on clinician diagnosis or risk factors such as prematurity, neonatal hypoxic ischemic encephalopathy, neonatal stroke, etc.).

During each study visit, sensors will be placed on the legs, arms, chest, and head using soft bandage wraps or a gentle adhesive. The sensors will record the child’s movements in various postures and tasks. Their movements will also be recorded on video.

These measurements will be completed at the approximate ages of 1-2 weeks, 1 months, 3 months, 6 months, 9 months, 1 year, and 2 years old. Each study visit will take about 1-2 hours.

Compensation will be provided.

If ever it’s too difficult to travel to one of these locations, another option is that we can come to you, and do a study visit at your home.

This study will test if low-dose oral minoxidil has aneffect on permanent chemotherapy-induced alopecia (defined as hair loss afterthe completion of a chemotherapy regimen that persists for over six months). Inthis study, you will receive the study drug; there is no placebo option. Theeffectiveness and safety of the treatment will be determined by a range of assessments,including biopsies, images, and subjective evaluation of perceived hair growth.

This is a clinical research study to test the safety and effectiveness of the study drug, pembrolizumab, in treating patients with an aggressive lymphoma or a histiocyte or dendritic cell neoplasm (tumor) that hasnot responded to or has come back after other treatments. The effectiveness and safety of the treatment will be determined by a range of assessments including biopsies, scans (or imaging tests), as well as general health and performance status.

Food allergy affects approximately 5-10% of young children, with highest incidence in the first year of life. Atopic dermatitis (eczema) is a major risk factor for food allergy and other allergic diseases, and it has a significant impact on child health. We hope to learn more about factors that put very young children at higher risk for food allergies and atopic dermatitis (eczema). This study with Dr. Amy Paller (Department of Dermatology), Dr. Emily Miller (Department of Obstetrics and Gynecology), and Dr. Rajesh Kumar (Department of Pediatrics-Allergy and Immunology) will focus on risk factors that may be present before, during, and after birth and through the age of 3 years. Identifying early life markers of those at risk could help with implementation of current prevention methods and discovery of new prevention methods.